Jonathan Fleming

Jonathan Fleming is the current chairman at Onc.AI, a precision medicine for the brain company developing therapies for patients suffering devastating neurological disease. Jonathan has also served as the chairman of the board at QurAlis from January 2017 to June 2022, and as a member of the board at CONTINUUS Pharmaceuticals, Inc. from January 2014 to April 2020. Additionally, they were a member of the board at SQZ Biotechnologies from January 2014 to December 2020. Jonathan Fleming received their MBA from the MIT Sloan School of Management and prior to that, they worked as a general partner at Oxford Bioscience Partners from January 1996 to December 2018.

Jonathan Fleming received their Master of Public Administration from Princeton University in Industrial Economics. Jonathan also holds a Bachelor of Arts from University of California, Berkeley.